Ocular Hypertension Following Intravitreal Anti-vascular Endothelial Growth Factor Agents

• Published in: Drugs & aging 2012-12, Vol.29 (12), p.949-956
• Main Authors: Singh, Ravi S. J., Kim, Judy E.
• Format: Article
• Language: English
• Subjects: Age; Antibodies; Biological and medical sciences; Clinical trials; FDA approval; Geriatrics/Gerontology; Glaucoma; Glaucoma and intraocular pressure; Humans; Hypertension; Internal Medicine; Intraocular Pressure - drug effects; Intravitreal Injections; Macular degeneration; Medical sciences; Medicine; Medicine & Public Health; Natural history; Ocular Hypertension - chemically induced; Ocular Hypertension - physiopathology; Ophthalmology; Patients; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Review Article; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual acuity
• ISSN: 1170-229X; 1179-1969
• DOI: 10.1007/s40266-012-0031-2

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in adults over the age of 65 years. The advent of anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections has revolutionized the management of exudative AMD. However, multiple case series of sustained elevated intraocular pressure (IOP) after intravitreal injections of anti-VEGF agents have been reported. Sustained elevated IOP has been reported with all anti-VEGF agents being used in ophthalmology and even in patients without any prior history of glaucoma. No clear correlations to injection frequency or patient characteristics have emerged from the multiple reports so far, but it appears that patients with pre-existing glaucoma or ocular hypertension and those receiving a greater number of injections with shorter injection intervals may be at a higher risk for developing ocular hypertension related to anti-VEGF agents. Until future studies elucidate the pathophysiology of sustained IOP following anti-VEGF injections, it is prudent to recognize the possibility of elevations in IOP in association with anti-VEGF therapy. Treating physicians should look for subtle optic nerve head changes and IOP measurements suspicious for glaucoma and have a low threshold for treating elevated IOP if the patient is likely to require multiple intravitreal anti-VEGF injections. Ocular hypertension following anti-VEGF injections appears to be amenable to anti-glaucoma treatment and every effort should be made to preserve the peripheral vision in these patients where central vision is already threatened by exudative AMD.